FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to ester prodrug forms of nalmefene of formula (I) 
wherein R1 means C6-16alkyl or C8-12alkylamino; or a pharmaceutically acceptable acid additive salt thereof. Also the invention claims the pharmaceutical compositions possessing action of an opioid receptor agonist containing a pharmaceutically acceptable salt and a therapeutically acceptable amount of the compound of formula (I).
EFFECT: invention describes the chemical methods for preparing the above compounds and using them in treating substance abuse disorders, such as abuse of alcohol and alcohol dependence, and pulse control disorders, such as compulsive gambling and shopping addiction.
14 cl, 5 ex, 1 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DIESTER NALMEFENE PRODRUGS | 2009 |
|
RU2495041C2 |
| ORGANIC COMPOUNDS | 2018 |
|
RU2777366C2 |
| THIA(DIA)ZOLES AS QUICK-DISSOCIATING ANTAGONISTS OF DOPAMINE 2 RECEPTOR | 2008 |
|
RU2489431C2 |
| BENZIMIDAZOLE DERIVATIVES EFFECTIVE IN TREATING CONDITIONS ASSOCIATED WITH P2X3 AND P2X2/3 ACTIVITY | 2010 |
|
RU2542582C2 |
| ORGANIC COMPOUNDS | 2018 |
|
RU2780002C2 |
| COMPOUNDS AND METHODS | 2015 |
|
RU2711442C2 |
| ORGANIC COMPOUNDS | 2019 |
|
RU2809023C2 |
| DERIVATIVES OF BETA-CARBOLINE POSSESSING EFFECT OF PHOSPHODIESTERASE INHIBITORS, PHARMACEUTICAL COMPOSITION (VARIANTS), METHOD FOR ITS PREPARING, METHOD FOR INHIBITION OF PHOSPHODIESTERASE EFFECT (VARIANTS) AND METHOD FOR INCREASING CGMP CONCENTRATION | 2001 |
|
RU2271358C2 |
| NEW COMPOSITIONS | 2021 |
|
RU2771565C1 |
| PHENYLCARBAMATES AND USE THEREOF AS ENZYME INHIBITORS OF HYDROLASES OF FATTY ACID AMIDES (FAAH) AND DOPAMINE RECEPTOR D3 (D3DR) MODULATORS | 2014 |
|
RU2693457C2 |
